Eruptive telangiectasia: a closer look at trastuzumab-emtansine cutaneous complications in breast cancer patients

Breast cancer, the most common malignancy in women, often involves overexpression of human epidermal growth factor receptor 2 (HER2), indicating poor prognosis. Trastuzumab-emtansine (TDM-1) emerges as a therapeutic option, yet its side effects, rarely include skin-related issues. Herein, we present a case of HER2-positive breast carcinoma undergoing TDM-1 treatment, manifesting eruptive telangiectatic macules, a previously under-reported adverse effect. Literature review reveals some cases associating cutaneous symptoms with hepatic abnormalities, highlighting potential systemic implications. Monitoring for liver damage, possibly through hepatic elastography, could aid in managing TDM-1-associated complications.